IOVA - NASDAQ
Iovance Biotherapeutics, Inc.
$4.43
+8.1%Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
At a Glance
Live SnapshotIovance Biotherapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Iovance Biotherapeutics, Inc. Income Statement
IOVA • NASDAQ
| Iovance Biotherapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||
263.5M | 164.1M | 1.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||||||||
(7.3M) | (124M) | (10.8M) | (0.0) | (0.0) | (0.0) | (8.1M) | (956K) | (952K) | (978K) | (999K) | (88.2K) | (4.7M) | (6.5M) | (19.3M) | (0.0) | (1.3K) | (0.0) | |
256.2M | 40.1M | -9.6M | 0.0 | 0.0 | 0.0 | -8.1M | -956K | -952K | -978K | -999K | -9.3M | -4.7M | -6.5M | -19.3M | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||||||||||||
(659.6M) | (435.4M) | (451M) | (398.9M) | (342.7M) | (261.9M) | (206.9M) | (128.3M) | (92.9M) | (53.6M) | (27.9M) | (2.7M) | (18M) | (8.1M) | (1.9M) | (815.4K) | (14.4K) | (57.1K) | |
(152.3M) | (153M) | (106.9M) | (104.1M) | (83.7M) | (60.2M) | (40.8M) | (28.4M) | (21.3M) | (17.2M) | (12.4M) | (9.3M) | (4.7M) | (6.5M) | (19.3M) | (756.8K) | (14.4K) | (25.6K) | |
(300.3M) | (282.3M) | (344.1M) | (294.8M) | (259M) | (201.7M) | (166M) | (99.8M) | (71.6M) | (28M) | (15.5M) | (2.7M) | (1.3M) | (1.7M) | (1.8M) | (0.0) | (0.0) | (0.0) | |
-403.4M | -395.3M | -460.6M | -398.9M | -342.7M | -261.9M | -206.9M | -128.3M | -92.9M | -53.6M | -27.9M | -12M | -22.6M | -8.1M | -21.2M | -815K | -15.8K | -57.1K | |
PRE-TAX INCOME | ||||||||||||||||||
(0.0) | (0.0) | (0.0) | (3M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (200K) | (5.7K) | (444.7K) | (2.4M) | (151.5K) | (0.0) | (0.0) | (0.0) | |
0.0 | 20.3M | 13M | 0.0 | 451K | 2.4M | 9.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(207M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (9.5M) | (0.0) | (0.0) | (16.7M) | (0.0) | (160K) | (815.4K) | (0.0) | (0.0) | |
10.3M | 20.3M | 13M | 3M | 451K | 2.4M | 9.3M | 4.7M | 813K | 745K | 200K | 5.7K | -2.7M | 4.8M | -4.5M | -793K | 0.0 | 0.0 | |
-393M | -375M | -447.5M | -395.9M | -342.3M | -259.6M | -197.6M | -123.6M | -92.1M | -52.9M | -27.7M | -12M | -25.4M | -3.3M | -25.7M | -1.6M | -15.8K | -57.1K | |
NET INCOME | ||||||||||||||||||
-2.1M | -2.8M | -3.5M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-391M | -372.2M | -444M | -395.9M | -342.3M | -259.6M | -197.6M | -123.6M | -92.1M | -52.9M | -27.7M | -12M | -25.4M | -3.3M | -25.7M | -1.6M | -15.8K | -57.1K |
SEC Filings
IOVA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 20, 2026 | March 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 09, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 29, 2025 | August 29, 2025 | 2025 |
Related Guides
Continue your IOVA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.